To confirm that recombinant anti-OLFML3 antibodies did not induce tumor cell death via ADCC or complement, we generated a glycosylation-deficient rec46A9 variant (rec46A9M) bearing a mutation in the Fc region at site N297 (N297Q) that prevents mAb recognition of Fc receptors by complement effectors. Here, OLFML3 is linked to neoplasm.